Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.69 |
| ▸ | RAB9A | P51151 | 4/20 | 0.69 |
| ▸ | HPGD | P15428 | 2/20 | 0.69 |
| ▸ | CRHBP | P24387 | 1/20 | 0.69 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.69 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.61 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17636723 | 0.95 | HPGD (0.77) | NPC1RAB9AHPGDCRHBPCRHR2 | |
| SCHEMBL7565510 | 0.89 | RAB9A (0.71) | NPC1RAB9AHPGDCRHBPCRHR2 | |
| SCHEMBL9188320 | 0.87 | HPGD (0.87) | NPC1RAB9AHPGDCRHBPCRHR2 | |
| SCHEMBL11790359 | 0.87 | RAB9A (0.65) | NPC1RAB9AHPGDCRHBPCRHR2 | |
| SCHEMBL21059104 | 0.86 | SMN1; SMN2 (0.65) | NPC1RAB9AHPGDSMN1; SMN2CYP1A2 | |
| SCHEMBL9515073 | 0.86 | LMNA (0.69) | NPC1RAB9AHPGDCRHBPCRHR2 | |
| SCHEMBL21059190 | 0.85 | RAB9A (0.73) | NPC1RAB9AHPGDSMN1; SMN2CYP1A2 | |
| SCHEMBL23727669 | 0.84 | MAPT (0.61) | NPC1RAB9AHPGDCYP1A2CYP2C19 | |
| SCHEMBL3230113 | 0.84 | SMN1; SMN2 (0.59) | NPC1RAB9AHPGDCRHBPCRHR2 | |
| SCHEMBL9377448 | 0.83 | NPC1 (0.61) | NPC1RAB9AHPGDCRHBPCRHR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102498095-A | Indoline derivatives | TOKYO INST TECH | 2012-06-13 | — | — | CN | claimed |
| US-20020010334-A1 | Processes to prepare pyrimidinediones | FMC CORPORATION | 2002-01-24 | — | — | US | claimed |
| EP-3508473-B1 | METHOD FOR PRODUCING CARBAMIC ACID ESTER | AIST (JP) | 2021-05-26 | — | — | EP | disclosed |
| US-10752579-B2 | Production method of carbamic acid ester | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2020-08-25 | — | — | US | disclosed |
| EP-3508473-A1 | METHOD FOR PRODUCING CARBAMIC ACID ESTER | National Institute of Advanced Industrial Science and Technology (JP) | 2019-07-10 | — | — | EP | disclosed |
| US-20190185420-A1 | PRODUCTION METHOD OF CARBAMIC ACID ESTER | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2019-06-20 | — | — | US | disclosed |
| CN-102498095-A | Indoline derivatives | TOKYO INST TECH | 2012-06-13 | — | — | CN | disclosed |
| US-7718795-B2 | Succinoylamino benzodiazepines as inhibitors of aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2010-05-18 | — | — | US | disclosed |
| US-7718795-B2 | Succinoylamino benzodiazepines as inhibitors of aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2010-05-18 | — | — | US | disclosed |
| US-7691558-B2 | Photosensitive composition, compound for use in the photosensitive composition and pattern forming method using the photosensitive composition | FUJIFILM CORPORATION (JP) | 2010-04-06 | — | — | US | disclosed |
| US-20090069293-A1 | SUCCINOYLAMINO BENZODIAZEPINES AS INHIBITORS OF AB PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2009-03-12 | — | — | US | disclosed |
| US-20080207602-A1 | SUCCINOYLAMINO BENZODIAZEPINES AS INHIBITORS OF ABETA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-08-28 | — | — | US | disclosed |
| US-20080171735-A1 | Coupling a solid phase bound succinic acid derivative by amidation to an aminolactam (1-methyl,2-oxo,3-amino,4-phenyl-2H-1,4-benzodiazepine) mediated by a uronium salt and a carbodiimide; releasing using dilute trifluoroacetic acid in dichloromethane; purified by chromatography; Alzeimer's; Down's | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-07-17 | — | — | US | disclosed |
| US-20080171735-A1 | Coupling a solid phase bound succinic acid derivative by amidation to an aminolactam (1-methyl,2-oxo,3-amino,4-phenyl-2H-1,4-benzodiazepine) mediated by a uronium salt and a carbodiimide; releasing using dilute trifluoroacetic acid in dichloromethane; purified by chromatography; Alzeimer's; Down's | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-07-17 | — | — | US | disclosed |
| US-7304049-B2 | Succinoylaminobenzodiazepines as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-12-04 | — | — | US | disclosed |
| US-7304049-B2 | Succinoylaminobenzodiazepines as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-12-04 | — | — | US | disclosed |
| US-20060122169-A1 | Succinoylamino benzodiazepines as inhibitors of Abeta protein production | DUPONT PHARMACEUTICALS (US) | 2006-06-08 | — | — | US | disclosed |
| US-20060122169-A1 | Succinoylamino benzodiazepines as inhibitors of Abeta protein production | DUPONT PHARMACEUTICALS (US) | 2006-06-08 | — | — | US | disclosed |
| US-20020010334-A1 | Processes to prepare pyrimidinediones | FMC CORPORATION | 2002-01-24 | — | — | US | disclosed |
| US-4600797-A | NITRATING AN AMINOBENZENE WHICH HAS A PROTECTEDD AMINO GROUP | BAYER AKTIENGESELLSCHAFT (DE) | 1986-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171735-A1 | Coupling a solid phase bound succinic acid derivative by amidation to an aminolactam (1-methyl,2-oxo,3-amino,4-phenyl-2H-1,4-benzodiazepine) mediated by a uronium salt and a carbodiimide; releasing using dilute trifluoroacetic acid in dichloromethane; purified by chromatography; Alzeimer's; Down's | PSEN1, APP, GABRA6 | NPC1 3562/4885RAB9A 3701/4885HPGD 2970/4885 |
| US-20090069293-A1 | SUCCINOYLAMINO BENZODIAZEPINES AS INHIBITORS OF AB PROTEIN PRODUCTION | GABRA5, APP, GABRE | NPC1 2506/4885RAB9A 1164/4885HPGD 1356/4885 |
| US-20190185420-A1 | PRODUCTION METHOD OF CARBAMIC ACID ESTER | CA2, CA7, CA4 | NPC1 2799/4885RAB9A 2467/4885HPGD 3008/4885 |
| US-20020010334-A1 | Processes to prepare pyrimidinediones | ALKBH1, CBR1, ALKBH3 | NPC1 3179/4885RAB9A 3747/4885HPGD 1170/4885 |
| US-20080207602-A1 | SUCCINOYLAMINO BENZODIAZEPINES AS INHIBITORS OF ABETA PROTEIN PRODUCTION | BACE1, APP, GABRE | NPC1 2364/4885RAB9A 1692/4885HPGD 1220/4885 |
| US-10752579-B2 | Production method of carbamic acid ester | CA2, CA7, CA4 | NPC1 2799/4885RAB9A 2467/4885HPGD 3008/4885 |
| US-20060122169-A1 | Succinoylamino benzodiazepines as inhibitors of Abeta protein production | BACE1, APP, GABRE | NPC1 2364/4885RAB9A 1692/4885HPGD 1220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.